PageSourceSearch

https://www.curasight.com/investor/the-share/

html curasight.com collected 2026-10-04 19:38:26 UTC 62,977 bytes, 565 lines download raw bytes

1<!DOCTYPE html>
2<html lang="en">
3<head>
4	
5
6<title>The Share - Curasight</title>
7<meta property="og:title" content="The Share - Curasight" />
8<meta name="twitter:title" content="The Share - Curasight" />
9<link rel="canonical" href="https://www.curasight.com/investor/the-share/">
10<meta charset="utf-8" />
11<meta http-equiv="X-UA-Compatible" content="IE=edge" />
12<meta name="viewport" content="width=device-width, initial-scale=1.0" />
13<meta property="og:url" content="https://www.curasight.com/investor/the-share/" />
14<meta name="twitter:url" content="https://www.curasight.com/investor/the-share/" />
15<meta property="og:type" content="website"/>
16
17<meta name="Description" content="" />
18<meta property="og:description" content="" />
19<meta name="twitter:description" content="" />
20<meta name="twitter:card" content="summary">
21
22
23<style id="_cssgrid">#_44-2{grid-area:1/1/21/25;}@media(max-width: 768px) {._section-container[data-id^="44-"] ._grid { display: block; }}
24#_74-1{grid-area:11/1/24/25;}#_74-2{grid-area:1/1/11/25;}#_74-3{grid-area:1/1/70/25;}#_74-4{grid-area:1/1/15/25;}#_74-5{grid-area:1/1/41/25;}#_74-6{grid-area:1/1/10/25;}@media(max-width: 768px) {._section-container[data-id^="74-"] ._grid { display: block; }}
25#_11-1{grid-area:15/1/41/17;}#_11-3{grid-area:1/1/12/25;}#_11-4{grid-area:1/17/38/25;}#_11-5{grid-area:1/1/15/13;}@media(max-width: 768px){#_11-1{grid-area:14/1/24/13;}#_11-3{grid-area:1/1/12/25;}#_11-4{grid-area:1/13/29/25;}#_11-5{grid-area:1/1/14/13;}}@media(max-width: 667px){#_11-1{grid-area:14/1/24/25;}#_11-3{grid-area:1/1/6/25;}#_11-4{grid-area:24/1/52/25;}#_11-5{grid-area:1/1/14/25;}}
26</style>
27<style id="_iegrid">#_44-2{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:20;-ms-grid-column-span:24;}#_74-1{-ms-grid-row:11;-ms-grid-column:1;-ms-grid-row-span:13;-ms-grid-column-span:24;}#_74-2{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:10;-ms-grid-column-span:24;}#_74-3{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:69;-ms-grid-column-span:24;}#_74-4{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:14;-ms-grid-column-span:24;}#_74-5{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:40;-ms-grid-column-span:24;}#_74-6{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:9;-ms-grid-column-span:24;}#_11-1{-ms-grid-row:15;-ms-grid-column:1;-ms-grid-row-span:26;-ms-grid-column-span:16;}#_11-3{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:11;-ms-grid-column-span:24;}#_11-4{-ms-grid-row:1;-ms-grid-column:17;-ms-grid-row-span:37;-ms-grid-column-span:8;}#_11-5{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:14;-ms-grid-column-span:12;}@media(max-width: 768px){#_11-1{-ms-grid-row:14;-ms-grid-column:1;-ms-grid-row-span:10;-ms-grid-column-span:12;}#_11-3{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:11;-ms-grid-column-span:24;}#_11-4{-ms-grid-row:1;-ms-grid-column:13;-ms-grid-row-span:28;-ms-grid-column-span:12;}#_11-5{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:13;-ms-grid-column-span:12;}}@media(max-width: 667px){#_11-1{-ms-grid-row:14;-ms-grid-column:1;-ms-grid-row-span:10;-ms-grid-column-span:24;}#_11-3{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:5;-ms-grid-column-span:24;}#_11-4{-ms-grid-row:24;-ms-grid-column:1;-ms-grid-row-span:28;-ms-grid-column-span:24;}#_11-5{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:13;-ms-grid-column-span:24;}}</style>
28
29
30<link rel="stylesheet" href="/main.css?1774614085395" type="text/css">
31
32
33
34<link rel="apple-touch-icon" sizes="180x180" href="/favicons/apple-touch-icon.png">
35<link rel="icon" type="image/png" sizes="32x32" href="/favicons/favicon-32x32.png">
36<link rel="icon" type="image/png" sizes="16x16" href="/favicons/favicon-16x16.png">
37<link rel="manifest" href="/favicons/site.webmanifest">
38<link rel="mask-icon" href="/favicons/safari-pinned-tab.svg" color="#446084">
39<link rel="shortcut icon" href="/favicons/favicon.ico">
40<meta name="msapplication-TileColor" content="#ffffff">
41<meta name="msapplication-config" content="/favicons/browserconfig.xml">
42<meta name="theme-color" content="#ffffff">
43
44
45
46
47
48
49
50
51
52</head>
53<body class="no-js live page74 sticky-all subnav-type-hover subnav-width-auto nav-thirdlevel-hidden nav-swipe-right nav-toggle-right">
54    <div id="top"></div>
55    <svg style="display: none;">
56    <symbol id="svg-Close" viewBox="0 0 44 44"><path d="M38.824 0L44 5.178 5.176 44 0 38.825 38.824 0z" fill="currentColor"></path><path d="M5.176 0L44 38.825 38.824 44 0 5.178 5.176 0z"  fill="currentColor"></path></symbol><symbol id="svg-Nav-hide" viewBox="0 0 26 26"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 1024 1024">
56<path fill="currentColor" d="M0 789q0 5 2 10t5 8q8 8 18.5 8t18.5-8l442-442 443 442q8 8 18.5 8t17.5-8q8-7 8-17.5t-8-18.5L504 310q-7-7-17.5-7t-18.5 7L7 771q-3 4-5 8.5T0 789z"/></svg></symbol><symbol id="svg-Nav-show" viewBox="0 0 26 26"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 1024 1024"><path fill="currentColor" d="M0 329q0-5 2-10t5-9q8-7 18.5-7t18.5 7l442 443 443-443q8-7 18.5-7t17.5 7q8 8 8 18.5t-8 18.5L504 807q-7 8-17.5 8t-18.5-8L7 347q-3-4-5-9t-2-10v1z"/></svg></symbol><symbol id="svg-LinkedIn" viewBox="0 0 1792 1792"><path d="M477 625v991H147V625h330zm21-306q1 73-50.5 122T312 490h-2q-82 0-132-49t-50-122q0-74 51.5-122.5T314 148t133 48.5T498 319zm1166 729v568h-329v-530q0-105-40.5-164.5T1168 862q-63 0-105.5 34.5T999 982q-11 30-11 81v553H659q2-399 2-647t-1-296l-1-48h329v144h-2q20-32 41-56t56.5-52 87-43.5T1285 602q171 0 275 113.5t104 332.5z" fill="currentColor"></path></symbol><symbol id="svg-YouTube-play" viewBox="0 0 147 147"><path d="M73.5 147C32.907 147 0 114.093 0 73.5S32.907 0 73.5 0 147 32.907 147 73.5 114.093 147 73.5 147zm29.01-73.29L55.59 50.327a2 2 0 0 0-2.892 1.79v46.767a2 2 0 0 0 2.892 1.79l46.92-23.384a2 2 0 0 0 0-3.58z" fill="currentColor" fill-rule="evenodd"></path></symbol><symbol id="svg-Search" viewBox="0 0 1792 1792"><path fill="currentColor" d="M1216 832q0-185-131.5-316.5t-316.5-131.5-316.5 131.5-131.5 316.5 131.5 316.5 316.5 131.5 316.5-131.5 131.5-316.5zm512 832q0 52-38 90t-90 38q-54 0-90-38l-343-342q-179 124-399 124-143 0-273.5-55.5t-225-150-150-225-55.5-273.5 55.5-273.5 150-225 225-150 273.5-55.5 273.5 55.5 225 150 150 225 55.5 273.5q0 220-124 399l343 343q37 37 37 90z"/></symbol><symbol id="svg-E-mail" viewBox="0 0 1792 1792"><path d="M1792 710v794q0 66-47 113t-113 47H160q-66 0-113-47T0 1504V710q44 49 101 87 362 246 497 345 57 42 92.5 65.5t94.5 48 110 24.5h2q51 0 110-24.5t94.5-48 92.5-65.5q170-123 498-345 57-39 100-87zm0-294q0 79-49 151t-122 123q-376 261-468 325-10 7-42.5 30.5t-54 38-52 32.5-57.5 27-50 9h-2q-23 0-50-9t-57.5-27-52-32.5-54-38T639 1015q-91-64-262-182.5T172 690q-62-42-117-115.5T0 438q0-78 41.5-130T160 256h1472q65 0 112.5 47t47.5 113z" fill="currentColor"></path></symbol>    
57</svg>
58
59
60
61
62<a class="_skiplink" id="_skiptocontent" href="#_main" accesskey="s"><span>Skip to main content</span></a><a class="_skiplink" id="_skiptonav" href="#_mainnav"><span>Skip to navigation</span></a><a class="_skiplink" id="_skiptosearch" href="#"><span>Skip to search</span></a>
63
64<header>
65    <div id="_mobile-header"><a class="_logotype" href="/"><img src="/files/images/curasight-site-logo.png" alt="Curasight"></a><button role="button" id="_toggle-nav" aria-expanded="false" aria-controls="_mobile-menu">
66        <span>
67            <span class="show">Menu</span>
68            <span class="hide">Close</span>
69        </span>
70    </button></div>
71    <div id="_mobile-menu" class="_mobile-menu">
72        <div class="_mobile-menu-row _row-0">
73    <div class="_searchform desktop-lightbox mob-regular">
74       <form action="/search/">
75            <input aria-label="Search" class="_searchbox" placeholder="Search" name="q" value="" autocomplete="off" /><button aria-label="Submit search"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792">
76        <use xlink:href="#svg-Search"></use>
77    </svg></button>
78            <div class="_instantsearch" data-nohits="No results found"></div>
79        </form>
80        
81        <button class="_toggleSearch" aria-hidden="true"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792">
82        <use xlink:href="#svg-Search"></use>
83    </svg></button>
84        
85    </div>
86</div>
87        <div id="_desktop-header"><div class="_cell-0-0"></div><div class="_cell-0-1"><a href="/investor/the-share/" id="_ticker"><div class="ticker">
88    <div class="_ticker-text">
89        <strong><span class="_ticker-price">&nbsp;</span> DKK</strong>
90        <span class="_ticker-changePerc">&nbsp;</span>%
91        | <span data-tickerformat="D MMM, YYYY" data-when="QuoteTime"></span>
92    </div>
93</div>
94</a><!-- --></div><div class="_cell-0-2"></div><div class="_cell-1-0"></div><div class="_cell-1-1"><a class="_logotype" href="/"><img src="/files/images/curasight-site-logo.png" alt="Curasight"></a><nav id="_mainnav" aria-label="Main navigation">
95<ul id="_menu1" class="level1" data-togglelabel="Toggle navigation"><li><a  href="/about-us/">About Us</a><ul id="_menu12" class="level2" aria-hidden="true"><li><a  href="/about-us/our-motivation/">Our Motivation</a></li><li><a  href="/about-us/management-team/">Management Team</a></li><li><a  href="/about-us/board-of-directors/">Board of Directors</a></li><li><a  href="/about-us/history/">History</a></li></ul></li><li><a  href="/upar-the-target/">uPAR – the Target</a><ul id="_menu16" class="level2" aria-hidden="true"><li><a  href="/upar-the-target/upar-theranostics/">uPAR Theranostics</a></li><li><a  href="/upar-the-target/utrace/">uTRACE®</a></li><li><a  href="/upar-the-target/utreat/">uTREAT®</a></li><li><a  href="/upar-the-target/disease-areas/">Disease Areas</a></li><li><a  href="/upar-the-target/publications/">Publications</a></li></ul></li><li><a  href="/pipeline/">Pipeline</a></li><li><a  href="/news/">News and Media</a><ul id="_menu27" class="level2" aria-hidden="true"><li><a  href="/news/press-releases/">Press releases</a></li><li><a  href="/news/presentations/">Presentations</a></li><li><a  href="/news/subscribe/">Subscribe</a></li><li><a  href="/news/frequently-asked-questions/">FAQ</a></li></ul></li><li class="expanded"><a  href="/investor/">Investor</a><ul id="_menu22" class="level2" aria-hidden="true"><li><a  href="/investor/curasight-as-an-investment/">Curasight as an investment</a></li><li><a  href="/investor/reports/">Financial reports</a></li><li class="expanded selected"><a  href="/investor/the-share/">The Share</a></li><li><a  href="/investor/general-meetings/">General meetings</a></li><li><a  href="/investor/calendar/">Calendar</a></li><li><a  href="/investor/events/">Events</a></li><li><a  href="/investor/corporate-governance/">Corporate Governance</a></li><li><a  href="/investor/analyst-coverage/">Analysts</a></li><li><a  href="/investor/archive-financing/">Archive financing</a></li></ul></li><li><a  href="/contact/">Contact</a></li></ul></nav>
96    <div class="_searchform desktop-lightbox mob-regular">
97       <form action="/search/">
98            <input aria-label="Search" class="_searchbox" placeholder="Search" name="q" value="" autocomplete="off" /><button aria-label="Submit search"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792">
99        <use xlink:href="#svg-Search"></use>
100    </svg></button>
101            <div class="_instantsearch" data-nohits="No results found"></div>
102        </form>
103        
104        <button class="_toggleSearch" aria-hidden="true"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792">
105        <use xlink:href="#svg-Search"></use>
106    </svg></button>
107        
108    </div>
109</div><div class="_cell-1-2"></div></div>
110        
111    </div>
112</header>
113    
114<nav class="breadcrumb" aria-label="Breadcrumb"><ul><li><a href="/">Home</a></li><li><a href="/investor/">Investor</a></li><li><p>The Share</p></li></ul></nav>
115
116    <div id="_middleregion"><div id="_leftregion">
117		<div data-id="44-1" class="_section-container">
118			
119			<div class="_section">
120				<div class="_grid">
121					
122            <div id="_44-2" class="_block">
123                
124        
125        <div class="_block-content">
126            
127<nav id="subnav" aria-label="Section">
128<h2><a href="/investor/">Investor</a></h2><ul><li><a href="/investor/curasight-as-an-investment/">Curasight as an investment</a></li><li><a href="/investor/reports/">Financial reports</a></li><li class="expanded"><a href="/investor/the-share/" class="selected">The Share</a></li><li><a href="/investor/general-meetings/">General meetings</a></li><li><a href="/investor/calendar/">Calendar</a></li><li><a href="/investor/events/">Events</a></li><li><a href="/investor/corporate-governance/">Corporate Governance</a></li><li><a href="/investor/analyst-coverage/">Analysts</a></li><li><a href="/investor/archive-financing/">Archive financing</a></li></ul>
129</nav>
130        </div>
131        
132    
133            </div>
134        
135				</div>
136			</div>
137			
138		</div>
139	</div><main id="_main">
140		<div data-id="74-1" class="_section-container">
141			
142			<div class="_section">
143				<div class="_grid">
144					
145            <div id="_74-2" class="_block">
146                
147        
148        <div class="_block-content">
149            <h1>The Share</h1>
150        </div>
151        
152    
153            </div>
154        
155            <div id="_74-1" class="_block">
156                
157        
158        <div class="_block-content">
159            <table class="share-summary share-summary--top">
160    <thead>
161        <tr>
162            <th><span data-tickerformat="dddd, D MMMM YYYY, HH:mm" data-when="QuoteTime"></span></th>
163            <th>Current</th>
164            <th>Change</th>
165            <th>Change (%)</th>
166        </tr>
167    </thead>
168    <tbody>
169        <tr>
170            <td>CURAS (Spotlight, Copenhagen) DKK/share</td>
171            <td><span class="_ticker-price"></span></td>
172            <td><span class="_ticker-change"></span></td>
173            <td><span class="_ticker-changePerc"></span></td>
174        </tr>
175    </tbody>
176</table>
177
178<table class="share-summary">
179    <thead>
180        <tr>
181            <th>Bid</th>
182            <th>Ask</th>
183            <th>High</th>
184            <th>Low</th>
185            <th>Volume</th>
186        </tr>
187    </thead>
188    <tbody>
189        <tr>
190            <td><span class="_ticker-bid"></span></td>
191            <td><span class="_ticker-ask"></span></td>
192            <td><span class="_ticker-high"></span></td>
193            <td><span class="_ticker-low"></span></td>
194            <td><span class="_ticker-volume"></span></td>
195        </tr>
196    </tbody>
197</table>
198
199        </div>
200        
201    
202            </div>
203        
204				</div>
205			</div>
206			
207		</div>
208	
209		<div data-id="74-2" class="_section-container">
210			
211			<div class="_section">
212				<div class="_grid">
213					
214            <div id="_74-3" class="_block">
215                
216        
217        <div class="_block-content">
218            
219<figure id="_sharegraph" class="_chart _sharegraph" data-color="#446084" data-symbol="CURAS" data-lang="en" data-divisor="1000" data-total-return-label="">
220    <div class="_shortcuts">
221        
222            <button data-type="1d" data-default="false">1D</button>
223        
224            <button data-type="5d" data-default="false">5D</button>
225        
226            <button data-type="1m" data-default="false">1M</button>
227        
228            <button data-type="6m" data-default="false">6M</button>
229        
230            <button data-type="1y" data-default="false">1Y</button>
231        
232            <button data-type="5y" data-default="false">5Y</button>
233        
234    </div>
235    
236    <div class="_peers">
237        <div></div>
238        
239        <label>
240            <input type="checkbox" data-color="#cccccc" data-symbol
240="SPTIDX">
241            <span>Spotlight Index (SEK)</span>
242        </label>
243        
244    </div>
245    
246    <div class="_chart-container">
247        <div class="_y-axis right"></div>
248        <div class="_y-axis right bottom"></div>
249        
250        <div class="_gridlines"></div>
251        <div class="_chart-area _margin">
252            <div class="_hoverline legend"></div>
253        </div>
254        <div class="_newsitems _margin"></div>
255        <div class="_volumeLabel">Volume, thousands</div>
256        <div class="_volume _margin"></div>
257        <div class="_timeline _margin">
258            <div class="_minor"></div>
259            <div class="_major"></div>
260        </div>
261        <div class="_navchart">
262            <div class="_leftcover _cover"></div>
263            <div class="_rightcover _cover"></div>
264            <div class="_handle _left"></div>
265            <div class="_navcover"></div>
266            <div class="_handle _right"></div>
267            <div class="_years"></div>
268            <svg xmlns="http://www.w3.org/2000/svg"></svg>
269        </div>
270    </div>
271    <div class="_newsjson">[{"d":"2026-01-05","n":"Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week","u":"/news/press-releases/2026/curasight-to-hold-meetings-in-san-francisco-during-j-p-morgan-healthcare-conference-week/"},{"d":"2026-01-12","n":"Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT[®] in High-Grade Gliomas","u":"/news/press-releases/2026/curasight-announces-encouraging-preliminary-data-from-phase-1-trial-evaluating-first-in-class-radiopharmaceutical-utreat-in-high-grade-gliomas/"},{"d":"2026-02-09","n":"Major Shareholding Notification","u":"/news/press-releases/2026/major-shareholding-notification/"},{"d":"2026-02-17","n":"Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston","u":"/news/press-releases/2026/curasight-to-present-at-td-cowens-46th-annual-health-care-conference-in-boston/"},{"d":"2026-02-26","n":"Year-end report Q4 2025","u":"/news/press-releases/2026/year-end-report-q4-2025/"},{"d":"2026-02-26","n":"Annual Report 2025","u":"/news/press-releases/2026/annual-report-2025/"},{"d":"2026-03-06","n":"Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade","u":"/news/press-releases/2026/curasight-reduces-convertible-debt-as-fenja-capital-converts-and-enters-into-a-block-trade/"},{"d":"2026-03-10","n":"Notice of Annual General Meeting 2026","u":"/news/press-releases/2026/notice-of-annual-general-meeting-2026/"},{"d":"2026-03-25","n":"Resolutions of the Annual General Meeting 2026 of Curasight A/S","u":"/news/press-releases/2026/resolutions-of-the-annual-general-meeting-2026-of-curasight-as/"},{"d":"2026-04-26","n":"Major Shareholding Notification - share transfer and ownership restructuring – related party transaction","u":"/news/press-releases/2026/major-shareholding-notification--share-transfer-and-ownership-restructuring-related-party-transaction/"},{"d":"2026-05-28","n":"Interim report Q1 2026","u":"/news/press-releases/2026/interim-report-q1-2026/"},{"d":"2026-06-08","n":"Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT[®] in Aggressive Brain Cancer (Glioblastoma)","u":"/news/press-releases/2026/curasight-announces-preliminary-readout-from-its-phase-1-clinical-trial-with-utreat-in-aggressive-brain-cancer-glioblastoma/"},{"d":"2026-06-22","n":"Curasight A/S announces its intention to carry out a directed issue of shares","u":"/news/press-releases/2026/curasight-as-announces-its-intention-to-carry-out-a-directed-issue-of-shares/"},{"d":"2026-06-22","n":"Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million","u":"/news/press-releases/2026/curasight-as-has-successfully-completed-a-directed-issue-of-shares-of-approximately-dkk-20-million/"},{"d":"2026-07-27","n":"Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive Brain Cancer (Glioblastoma)","u":"/news/press-releases/2026/curasight-announces-protocol-update-for-the-phase-i-utreat-trial-in-aggressive-brain-cancer-glioblastoma/"},{"d":"2026-08-27","n":"Curasight publishes Interim Report Q2 2026","u":"/news/press-releases/2026/curasight-publishes-interim-report-q2-2026/"},{"d":"2026-09-14","n":"Major Shareholding Notification - ownership restructuring – related party transaction","u":"/news/press-releases/2026/major-shareholding-notification--ownership-restructuring-related-party-transaction/"},{"d":"2025-09-03","n":"Transaction with shares in Curasight A/S made by managerial employee","u":"/news/press-releases/2025/transaction-with-shares-in-curasight-as-made-by-managerial-employee/"},{"d":"2025-10-01","n":"Curasight announces broadening and extension of patent protection for uTRACE®","u":"/news/press-releases/2025/curasight-announces-broadening-and-extension-of-patent-protection-for-utrace/"},{"d":"2025-10-29","n":"Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting","u":"/news/press-releases/2025/curasight-advances-phase-2-utrace-prostate-cancer-trial-with-all-european-clinical-sites-in-part-2-now-recruiting/"},{"d":"2025-11-13","n":"Curasight to present at Dansk Aktionærforening InvestorDagen","u":"/news/press-releases/2025/curasight-to-present-at-dansk-aktionaerforening-investordagen/"},{"d":"2025-11-26","n":"Curasight’s uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment","u":"/news/press-releases/2025/curasights-utreat-phase-1-trial-in-brain-cancer-now-open-for-patient-enrollment/"},{"d":"2025-11-27","n":"Interim report Q3 2025","u":"/news/press-releases/2025/interim-report-q3-2025/"},{"d":"2025-11-28","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2025/curasight-to-present-at-hc-andersen-capital-2025-11-28/"},{"d":"2025-12-12","n":"Curasight A/S announces its intention to carry out a directed issue of shares and enter into a 
271new loan facility","u":"/news/press-releases/2025/curasight-as-announces-its-intention-to-carry-out-a-directed-issue-of-shares-and-enter-into-a-new-loan-facility/"},{"d":"2025-12-12","n":"Curasight A/S has successfully completed a directed issue of shares of approximately DKK 16.4 million and has entered into a new loan facility","u":"/news/press-releases/2025/curasight-as-has-successfully-completed-a-directed-issue-of-shares-of-approximately-dkk-16-4-million-and-has-entered-into-a-new-loan-facility/"},{"d":"2025-12-14","n":"Notice of Extraordinary General Meeting","u":"/news/press-releases/2025/notice-of-extraordinary-general-meeting/"},{"d":"2025-12-18","n":"Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT[®] in Brain Cancer","u":"/news/press-releases/2025/curasight-announces-successful-dosing-of-first-patient-in-phase-1-trial-with-utreat-in-brain-cancer/"},{"d":"2025-12-29","n":"Resolutions of the Extraordinary General Meeting December 2025","u":"/news/press-releases/2025/resolutions-of-the-extraordinary-general-meeting-december-2025/"},{"d":"2025-12-29","n":"Curasight A/S resolves to issue a convertible loan note","u":"/news/press-releases/2025/curasight-as-resolves-to-issue-a-convertible-loan-note/"},{"d":"2025-02-05","n":"Curasight announces an updated financial calendar 2025","u":"/news/press-releases/2025/curasight-announces-an-updated-financial-calendar-2025/"},{"d":"2025-02-27","n":"Year-end report Q4 2024","u":"/news/press-releases/2025/year-end-report-q4-2024/"},{"d":"2025-03-26","n":"Curasight announces new date of the Annual General Meeting and an updated financial calendar 2025","u":"/news/press-releases/2025/curasight-announces-new-date-of-the-annual-general-meeting-and-an-updated-financial-calendar-2025/"},{"d":"2025-04-04","n":"Curasight A/S resolves on its intention to carry out a rights issue of shares of approximately DKK 100 million","u":"/news/press-releases/2025/curasight-as-resolves-on-its-intention-to-carry-out-a-rights-issue-of-shares-of-approximately-dkk-100-million/"},{"d":"2025-04-08","n":"Notice of Extraordinary General Meeting of Curasight A/S","u":"/news/press-releases/2025/notice-of-extraordinary-general-meeting-of-curasight-as/"},{"d":"2025-04-23","n":"Resolutions of the Extraordinary General Meeting of Curasight A/S on 23 April 2025","u":"/news/press-releases/2025/resolutions-of-the-extraordinary-general-meeting-of-curasight-as-on-23-april-2025/"},{"d":"2025-04-24","n":"CURASIGHT A/S ANNOUNCES FINAL TERMS OF RIGHTS ISSUE","u":"/news/press-releases/2025/curasight-as-announces-final-terms-of-rights-issue/"},{"d":"2025-04-25","n":"Interim report Q1 2025","u":"/news/press-releases/2025/interim-report-q1-2025/"},{"d":"2025-04-25","n":"Annual Report for the fiscal year 2024","u":"/news/press-releases/2025/annual-report-for-the-fiscal-year-2024/"},{"d":"2025-04-29","n":"Curasight A/S publishes disclosure document regarding rights issue","u":"/news/press-releases/2025/curasight-as-publishes-disclosure-document-regarding-rights-issue/"},{"d":"2025-04-30","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2025/curasight-to-present-at-hc-andersen-capital/"},{"d":"2025-05-02","n":"THE SUBSCRIPTION PERIOD IN CURASIGHT’S RIGHTS ISSUE OF SHARES BEGINS TODAY","u":"/news/press-releases/2025/the-subscription-period-in-curasights-rights-issue-of-shares-begins-today/"},{"d":"2025-05-07","n":"Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer","u":"/news/press-releases/2025/curasight-as-selects-cro-to-run-phase-1-trial-with-utreat-in-brain-cancer/"},{"d":"2025-05-13","n":"Last day of the subscription period in Curasight’s rights issue of shares","u":"/news/press-releases/2025/last-day-of-the-subscription-period-in-curasights-rights-issue-of-shares/"},{"d":"2025-05-13","n":"Notice of Annual General Meeting 2025","u":"/news/press-releases/2025/notice-of-annual-general-meeting-2025/"},{"d":"2025-05-15","n":"Subscription of new shares in the Right Issue 2025 exercised by Curasight management","u":"/news/press-releases/2025/subscription-of-new-shares-in-the-right-issue-2025-exercised-by-curasight-management/"},{"d":"2025-05-21","n":"Curasight announces outcome in rights issue","u":"/news/press-releases/2025/curasight-announces-outcome-in-rights-issue/"},{"d":"2025-05-28","n":"Resolutions of the Annual General Meeting 2025 of Curasight A/S","u":"/news/press-releases/2025/resolutions-of-the-annual-general-meeting-2025-of-curasight-as/"},{"d":"2025-05-28","n":"Completed registration of rights issue","u":"/news/press-releases/2025/completed-registration-of-rights-issue/"},{"d":"2025-06-02","n":"Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue","u":"/news/press-releases/2025/curasight-carries-out-a-directed-issue-of-shares-to-guarantors-in-connection-with-the-completed-rights-issue/"},{"d":"2025-06-03","n":"The exercise period commences for warrants of series TO3 on 4 June 2025","u":"/news/press-releases/2025/the-exercise-period-commences-for-warrants-of-series-to3-on-4-june-2025/"},{"d":"2025-06-18","n":"Curasight A/S submits Clinical Trial Application for Phase 1 trial with uTREAT[®] in brain cancer patients","u":"/news/press-releases/2025/curasight-as-submits-clinical-trial-application-for-phase-1-trial-with-utreat-in-brain-cancer-patients/"},{"d":"2025-06-23","n":"Curasight A/S announces outcome of T03 warrant exercise","u":"/news/press-releases/2025/curasight-as-announces-outcome-of-t03-warrant-exercise/"},{"d":"2025-08-26","n":"Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT[®] in brain cancer patients","u":"/news/press-releases/2025/curasight-announces-acceptance-of-clinical-trial-application-cta-for-phase-1-trial-with-utreat-in-brain-cancer-patients/"},{"d":"2025-08-28","n":"Half-year report Q2 2025","u":"/news/press-releases/2025/half-year-report-q2-2025/"},{"d":"2024-01-22","n":"Curasight A/S Achieves First Milestone under collaboration with Curium Inc.","u":"/news/press-releases/2024/curasight-as-achieves-first-milestone-under-collaboration-with-curium-inc/"},{"d":"2024-02-13","n":"Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company","u":"/news/press-releases/2024/curasight-announces-acceleration-of-therapeutic-strategy-to-strengthen-position-as-a-radiopharmaceutical-theranostic-company/"},{"d":"2024-02-13","n":"Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy","u":"/investor/archive-financing/rights-issue-2024/curasight-resolves-on-a-rights-issue-of-up-to-dkk-51-2-million-to-accelerate-its-therapeutic-strategy/"},{"d":"2024-02-22","n":"Year-end report October – December 2023","u":"/news/press-releases/2024/year-end-report-october-december-2023/"},{"d":"2024-02-22","n":"Annual Report for the fiscal year 2023","u":"/news/press-releases/2024/annual-report-for-the-fiscal-year-2023/"},{"d":"2024-02-22","n":"Curasight publishes information memorandum in connection with forthcoming rights issue","u":"/investor/archive-financing/rights-issue-2024/curasight-publishes-information-memorandum-in-connection-with-forthcoming-rights-issue/"},{"d":"2024-02-23","n":"The subscription period in Curasight’s rights issue begins today","u":"/investor/archive-financing/rights-issue-2024/the-subscription-period-in-curasights-rights-issue-begins-today/"},{"d":"2024-03-06","n":"Notice of Annual General Meeting 2024","u":"/news/press-releases/2024/notice-
271of-annual-general-meeting-2024/"},{"d":"2024-03-11","n":"Curasight not to proceed with rights issue; evaluating alternative financing opportunities","u":"/news/press-releases/2024/curasight-not-to-proceed-with-rights-issue-evaluating-alternative-financing-opportunities/"},{"d":"2024-03-21","n":"Resolutions of the Annual General Meeting 2024 of Curasight A/S","u":"/news/press-releases/2024/resolutions-of-the-annual-general-meeting-2024-of-curasight-as/"},{"d":"2024-04-12","n":"Curasight announces change in the Board of Directors","u":"/news/press-releases/2024/curasight-announces-change-in-the-board-of-directors/"},{"d":"2024-04-16","n":"Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients","u":"/news/press-releases/2024/curasight-announces-approval-of-clinical-trial-application-cta-for-phase-2-trial-with-utrace-in-prostate-cancer-patients/"},{"d":"2024-05-23","n":"Interim report Q1 2024","u":"/news/press-releases/2024/interim-report-q1-2024/"},{"d":"2024-06-12","n":"Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer","u":"/news/press-releases/2024/curasight-announces-enrollment-of-first-patient-in-phase-2-trial-with-utrace-in-prostate-cancer/"},{"d":"2024-06-14","n":"Curasight A/S resolves on directed issues and a loan facility","u":"/news/press-releases/2024/curasight-as-resolves-on-directed-issues-and-a-loan-facility/"},{"d":"2024-06-17","n":"Notice of Extraordinary General Meeting","u":"/news/press-releases/2024/notice-of-extraordinary-general-meeting/"},{"d":"2024-06-22","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2024/curasight-to-present-at-hc-andersen-capital/"},{"d":"2024-07-01","n":"Directed issues registered at the Danish Business Authority","u":"/news/press-releases/2024/directed-issues-registered-at-the-danish-business-authority/"},{"d":"2024-07-02","n":"Resolutions of the Extraordinary General Meeting of Curasight A/S on 2 July 2024","u":"/news/press-releases/2024/resolutions-of-the-extraordinary-general-meeting-of-curasight-as-on-2-july-2024/"},{"d":"2024-07-30","n":"Curasight issues warrants as part of long-term incentive program","u":"/news/press-releases/2024/curasight-issues-warrants-as-part-of-long-term-incentive-program/"},{"d":"2024-08-22","n":"Interim report Q2 2024","u":"/news/press-releases/2024/interim-report-q2-2024/"},{"d":"2024-09-04","n":"The Board of Directors resolves on a directed issue of units and preferential rights issue of units","u":"/news/press-releases/2024/the-board-of-directors-resolves-on-a-directed-issue-of-units-and-preferential-rights-issue-of-units/"},{"d":"2024-09-12","n":"Curasight A/S publishes prospectus due to upcoming rights issue","u":"/news/press-releases/2024/curasight-as-publishes-prospectus-due-to-upcoming-rights-issue/"},{"d":"2024-09-16","n":"Commencement of subscription period in Curasight’s preferential rights issue","u":"/news/press-releases/2024/commencement-of-subscription-period-in-curasights-preferential-rights-issue/"},{"d":"2024-10-03","n":"Curasight A/S rights issue heavily oversubscribed","u":"/news/press-releases/2024/curasight-as-rights-issue-heavily-oversubscribed/"},{"d":"2024-10-11","n":"Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3","u":"/news/press-releases/2024/curasight-as-announces-last-day-of-trading-in-btu-and-first-day-of-trading-in-warrant-series-to2-and-to3/"},{"d":"2024-11-07","n":"Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer","u":"/news/press-releases/2024/clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients-published-data-supports-development-of-utreat-for-brain-cancer/"},{"d":"2024-11-08","n":"Curasight to present at Dansk Aktionærforening InvestorDagen","u":"/news/press-releases/2024/curasight-to-present-at-dansk-aktionaerforening-investordagen/"},{"d":"2024-11-11","n":"Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025","u":"/news/press-releases/2024/curasight-announces-brain-cancer-as-first-indication-for-utreat-first-patient-to-be-dosed-q2-2025/"},{"d":"2024-11-13","n":"Curasight announces international patent application for uTREAT® to broaden IP protection","u":"/news/press-releases/2024/curasight-announces-international-patent-application-for-utreat-to-broaden-ip-protection/"},{"d":"2024-11-14","n":"Curasight to present at HC Andersen Capital, BioStock Life Science Summit 2024, and Økonomisk Ugebrev Investor Conference","u":"/news/press-releases/2024/curasight-to-present-at-hc-andersen-capital-biostock-life-science-summit-2024-and-okonomisk-ugebrev-investor-conference/"},{"d":"2024-11-20","n":"The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share","u":"/news/press-releases/2024/the-exercise-price-for-warrants-of-series-to2-has-been-set-to-dkk-11-50-per-new-share/"},{"d":"2024-11-21","n":"Interim report Q3 2024","u":"/news/press-releases/2024/interim-report-q3-2024/"},{"d":"2024-11-21","n":"The exercise period for warrants of series TO2 commences today","u":"/news/press-releases/2024/the-exercise-period-for-warrants-of-series-to2-commences-today/"},{"d":"2024-11-22","n":"Curasight and Curium sign global radioisotope supply agreement for uTREAT[®]","u":"/news/press-releases/2024/curasight-and-curium-sign-global-radioisotope-supply-agreement-for-utreat/"},{"d":"2024-12-02","n":"The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024","u":"/news/press-releases/2024/the-last-day-of-trading-in-warrants-of-series-to2-is-on-the-3rd-of-december-2024/"},{"d":"2024-12-02","n":"SEB maintain valuation range midpoint at DKK 54 per share","u":"/news/press-releases/2024/seb-maintain-valuation-range-midpoint-at-dkk-54-per-share/"},{"d":"2024-12-10","n":"Curasight A/S announces outcome of warrant exercise","u":"/news/press-releases/2024/curasight-as-announces-outcome-of-warrant-exercise/"},{"d":"2024-12-10","n":"Participation in warrant exercise by Curasight management","u":"/news/press-releases/2024/participation-in-warrant-exercise-by-curasight-management/"},{"d":"2023-01-16","n":"Curasight to present at Redeye Fight Cancer Seminar","u":"/news/press-releases/2023/curasight-to-present-at-redeye-fight-cancer-seminar/"},{"d":"2023-02-22","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital/"},{"d":"2023-02-23","n":"Year-end report October - December 2022","u":"/news/press-releases/2023/year-end-report-october---december-2022/"},{"d":"2023-02-23","n":"Annual Report for the fiscal year 2022","u":"/news/press-releases/2023/annual-report-for-the-fiscal-year-2022/"},{"d":"2023-03-15","n":"Notice of Annual General Meeting 2023","u":"/news/press-releases/2023/notice-
271of-annual-general-meeting-2023/"},{"d":"2023-03-30","n":"Resolutions of the Annual General Meeting of Curasight A/S","u":"/news/press-releases/2023/resolutions-of-the-annual-general-meeting-of-curasight-as/"},{"d":"2023-05-01","n":"Curasight and Curium announce global partnership for uTRACE[®] in prostate cancer","u":"/news/press-releases/2023/curasight-and-curium-announce-global-partnership-for-utrace-in-prostate-cancer/"},{"d":"2023-05-25","n":"Interim report Q1 2023","u":"/news/press-releases/2023/interim-report-q1-2023/"},{"d":"2023-05-26","n":"Curasight to present at HC Andersen Capital and Økonomisk Ugebrev","u":"/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital-and-okonomisk-ugebrev/"},{"d":"2023-06-07","n":"Curasight A/S reports positive preclinical results with uTREAT[®] in aggressive brain cancer (glioblastoma)","u":"/news/press-releases/2023/curasight-as-reports-positive-preclinical-results-with-utreat-in-aggressive-brain-cancer-glioblastoma/"},{"d":"2023-06-29","n":"Positive results in uPAR-PET/MR Phase II study in brain cancer","u":"/news/press-releases/2023/positive-results-in-upar-petmr-phase-ii-study-in-brain-cancer/"},{"d":"2023-08-24","n":"Interim Report January – June 2023","u":"/news/press-releases/2023/interim-report-january--june-2023/"},{"d":"2023-08-25","n":"Curasight to present at HC Andersen Capital and at HC Andersen Life Science seminar","u":"/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital-and-at-hc-andersen-life-science-seminar/"},{"d":"2023-09-14","n":"Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague","u":"/news/press-releases/2023/positive-results-from-the-phase-ii-study-of-utrace-in-brain-cancer-presented-at-the-world-molecular-imaging-congress-wmic-2023-in-prague/"},{"d":"2023-10-18","n":"Curasight A/S reports positive preclinical results with uTREAT[®] in lung cancer (NSCLC)","u":"/news/press-releases/2023/curasight-as-reports-positive-preclinical-results-with-utreat-in-lung-cancer-nsclc/"},{"d":"2023-11-23","n":"Interim Report January – September 2023","u":"/news/press-releases/2023/interim-report-january--september-2023/"},{"d":"2023-11-24","n":"Curasight to present at HC Andersen Capital and Stokk.io","u":"/news/press-releases/2023/curasight-to-present-at-hc-andersen-capital-and-stokkio/"},{"d":"2023-12-13","n":"Curasight A/S appoints CRO to run Phase 2 study with uTRACE[®] in prostate cancer","u":"/news/press-releases/2023/curasight-as-appoints-cro-to-run-phase-2-study-with-utrace-in-prostate-cancer/"},{"d":"2023-12-18","n":"Curasight A/S submits clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients","u":"/news/press-releases/2023/curasight-as-submits-clinical-trial-application-cta-for-phase-2-trial-with-utrace-in-prostate-cancer-patients/"},{"d":"2022-01-18","n":"Curasight presents at the SEB Nordic Healthcare Seminar 2022 and at Kapital Partner","u":"/news/press-releases/2022/curasight-presents-at-the-seb-nordic-healthcare-seminar-2022-and-at-kapital-partner/"},{"d":"2022-01-27","n":"Phase II study of uPAR-PET in neuroendocrine tumor patients demonstrates strong prognostic value and supports potential future use of uPAR-targeted radionuclide therapy","u":"/news/press-releases/2022/phase-ii-study-of-upar-pet-in-neuroendocrine-tumor-patients-demonstrates-strong-prognostic-value-and-supports-potential-future-use-of-upar-targeted-radionuclide-therapy/"},{"d":"2022-02-10","n":"Curasight strengthens its strategic position with the acquisition of TRT Innovations ApS","u":"/news/press-releases/2022/curasight-strengthens-its-strategic-position-with-the-acquisition-of-trt-innovations-aps/"},{"d":"2022-02-23","n":"Curasight expands its strategy and strengthen its position as a theranostic company","u":"/news/press-releases/2022/curasight-expands-its-strategy-and-strengthen-its-position-as-a-theranostic-company/"},{"d":"2022-02-24","n":"Year-end report October - December 2021","u":"/news/press-releases/2022/year-end-report-october---december-2021/"},{"d":"2022-02-24","n":"Annual Report for the fiscal year 2021","u":"/news/press-releases/2022/annual-report-for-the-fiscal-year-2021/"},{"d":"2022-03-09","n":"Curasight announces new date of the Annual General Meeting and an updated financial calendar 2022","u":"/news/press-releases/2022/curasight-announces-new-date-of-the-annual-general-meeting-and-an-updated-financial-calendar-2022/"},{"d":"2022-04-12","n":"Notice of Annual General Meeting 2022","u":"/news/press-releases/2022/notice-
271of-annual-general-meeting-2022/"},{"d":"2022-04-22","n":"Additional US patent application relating to uTRACE[®] is accepted for grant","u":"/news/press-releases/2022/additional-us-patent-application-relating-to-utrace-is-accepted-for-grant/"},{"d":"2022-04-27","n":"Resolutions of the Annual General Meeting of Curasight A/S","u":"/news/press-releases/2022/resolutions-of-the-annual-general-meeting-of-curasight-as/"},{"d":"2022-05-16","n":"Curasight to present at Kapital Partners Life Science seminar","u":"/news/press-releases/2022/curasight-to-present-at-kapital-partners-life-science-seminar/"},{"d":"2022-05-24","n":"Interim Report January - March 2022","u":"/news/press-releases/2022/interim-report-january---march-2022/"},{"d":"2022-06-07","n":"Curasight issues warrants for launch of long-term incentive program","u":"/news/press-releases/2022/curasight-issues-warrants-for-launch-of-long-term-incentive-program/"},{"d":"2022-06-24","n":"Transaction with shares in Curasight A/S made by managerial employee","u":"/news/press-releases/2022/transaction-with-shares-in-curasight-as-made-by-managerial-employee/"},{"d":"2022-06-30","n":"Recruitment completed in uPAR-PET study in brain cancer","u":"/news/press-releases/2022/recruitment-completed-in-upar-pet-study-in-brain-cancer/"},{"d":"2022-08-25","n":"Interim Report January – June 2022","u":"/news/press-releases/2022/interim-report-january--june-2022/"},{"d":"2022-08-25","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2022/curasight-to-present-at-hc-andersen-capital/"},{"d":"2022-09-04","n":"Transaction with shares in Curasight A/S made by managerial employee","u":"/news/press-releases/2022/transaction-with-shares-in-curasight-as-made-by-managerial-employee-2022-09-04/"},{"d":"2022-10-13","n":"Curasight initiates pre-clinical studies with uTREAT[®] therapy in head and neck cancer (HNSCC) and neuroendocrine tumors (NET)","u":"/news/press-releases/2022/curasight-initiates-pre-clinical-studies-with-utreat-therapy-in-head-and-neck-cancer-hnscc-and-neuroendocrine-tumors-net/"},{"d":"2022-11-17","n":"Curasight to present at SEB Healthcare Seminar 2022","u":"/news/press-releases/2022/curasight-to-present-at-seb-healthcare-seminar-2022/"},{"d":"2022-11-23","n":"Curasight to present at HC Andersen Capital","u":"/news/press-releases/2022/curasight-to-present-at-hc-andersen-capital-2022-11-23/"},{"d":"2022-11-24","n":"Interim Report January – September 2022","u":"/news/press-releases/2022/interim-report-january--september-2022/"},{"d":"2021-09-01","n":"Curasight A/S strengthens its institutional investor base","u":"/news/press-releases/2021/curasight-as-strengthens-its-institutional-investor-base/"},{"d":"2021-09-16","n":"The exercise period for warrants of series TO 1 in Curasight A/S begins today","u":"/news/press-releases/2021/the-exercise-period-for-warrants-of-series-to-1-in-curasight-as-begins-today/"},{"d":"2021-09-21","n":"Transactions with warrants of series TO 1 in Curasight A/S made by managerial employees and their closely associated persons","u":"/news/press-releases/2021/transactions-with-warrants-of-series-to-1-in-curasight-as-made-by-managerial-employees-and-their-closely-associated-persons/"},{"d":"2021-09-30","n":"Curasight warrant TO 1 – last day of trading is Tuesday 5 October 2021","u":"/news/press-releases/2021/curasight-warrant-to-1--last-day-of-trading-is-tuesday-5-october-2021/"},{"d":"2021-10-11","n":"Curasight A/S receives approximately DKK 47.6 million through exercise of warrants of series TO 1","u":"/news/press-releases/2021/curasight-as-receives-approximately-dkk-476-million-through-exercise-of-warrants-of-series-to-1/"},{"d":"2021-10-13","n":"Curasight A/S warrant exercise registered at Erhvervsstyrelsen","u":"/news/press-releases/2021/curasight-as-warrant-exercise-registered-at-erhvervsstyrelsen/"},{"d":"2021-10-15","n":"Curasight A/S presents at BioStock Life Science Summit 20 October 2021","u":"/news/press-releases/2021/curasight-as-presents-at-biostock-life-science-summit-20-october-2021/"},{"d":"2021-10-15","n":"Curasight A/S presents at Økonomisk Ugebrev Life Science Investor Conference in Copenhagen 20 October 2021","u":"/news/press-releases/2021/curasight-as-presents-at-okonomisk-ugebrev-life-science-investor-conference-in-copenhagen-20-october-2021/"},{"d":"2021-11-23","n":"Curasight presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-presents-at-hc-andersen-capital-2021-11-23/"},{"d":"2021-11-25","n":"Interim report January – September 2021","u":"/news/press-releases/2021/interim-report-january--september-2021/"},{"d":"2021-12-06","n":"Curasight A/S presents at Sedermeradagen in Copenhagen 7 December 2021","u":"/news/press-releases/2021/curasight-as-presents-at-sedermeradagen-in-copenhagen-7-december-2021/"},{"d":"2021-12-07","n":"Curasight A/S presents at HC Andersen Capital & Nordea Markets Virtual Growth Days seminar - 9 December 2021","u":"/news/press-releases/2021/curasight-as-presents-at-hc-andersen-capital--nordea-markets-virtual-growth-days-seminar---9-december-2021/"},{"d":"2021-12-09","n":"Phase II study demonstrates prognostic value of uPAR-PET in head and neck cancer patients","u":"/news/press-releases/2021/phase-ii-study-demonstrates-prognostic-value-of-upar-pet-in-head-and-neck-cancer-patients/"},{"d":"2021-12-13","n":"Curasight presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-presents-at-hc-andersen-capital-2021-12-13/"},{"d":"2021-12-14","n":"Transaction with shares in Curasight A/S made by managerial employee","u":"/news/press-releases/2021/transaction-with-shares-in-curasight-as-made-by-managerial-employee/"},{"d":"2021-12-21","n":"Hanne Damgaard Jensen joins Curasight A/S as Chief Development Officer (CDO)","u":"/news/press-releases/2021/hanne-damgaard-jensen-joins-curasight-as-as-chief-development-officer-cdo/"},{"d":"2021-12-30","n":"Curasight attends the J.P. Morgan Healthcare Conference and presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-attends-the-jp-morgan-healthcare-conference-and-presents-at-hc-andersen-capital/"},{"d":"2021-08-24","n":"Interim report January – June 2021","u":"/news/press-releases/2021/interim-report-january--june-2021/"},{"d":"2021-08-23","n":"Curasight presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-presents-at-hc-andersen-capital/"},{"d":"2021-02-08","n":"US patent application 14/399,820 relating to uTREAT[®] is accepted for grant","u":"/news/press-releases/2021/us-patent-application-14399820-relating-to-utreat-is-accepted-for-grant/"},{"d":"2021-02-24","n":"Year-end report October – December 2020","u":"/news/press-releases/2021/year-end-report-october--december-2020/"},{"d":"2021-02-24","n":"Annual Report for the fiscal year 2020","u":"/news/press-releases/2021/annual-report-for-the-fiscal-year-2020/"},{"d":"2021-02-26","n":"Article from Phase II study in prostate cancer now published in the March issue of Journ
271al of Nuclear Medicine and highlighted as best clinical investigation article","u":"/news/press-releases/2021/article-from-phase-ii-study-in-prostate-cancer-now-published-in-the-march-issue-of-journal-of-nuclear-medicine-and-highlighted-as-best-clinical-investigation-article/"},{"d":"2021-03-05","n":"Curasight A/S presents at Økonomisk Ugebrev Life Science Investor Conference","u":"/news/press-releases/2021/curasight-as-presents-at-okonomisk-ugebrev-life-science-investor-conference/"},{"d":"2021-03-11","n":"Notice of Annual General Meeting","u":"/news/press-releases/2021/notice-of-annual-general-meeting/"},{"d":"2021-03-11","n":"Curasight’s presentation at Økonomisk Ugebrev Life Science Investor Conference is now available","u":"/news/press-releases/2021/curasights-presentation-at-okonomisk-ugebrev-life-science-investor-conference-is-now-available/"},{"d":"2021-03-25","n":"Minutes from the Annual General Meeting in Curasight A/S","u":"/news/press-releases/2021/minutes-from-the-annual-general-meeting-in-curasight-as/"},{"d":"2021-03-28","n":"CAD patent application 2,905,172 relating to uTREAT[®] is accepted for grant","u":"/news/press-releases/2021/cad-patent-application-2905172-relating-to-utreat-is-accepted-for-grant/"},{"d":"2021-04-09","n":"Curasight A/S presents at Nordnet Live - Spotlight Small Cap investor conference 15 April 2021","u":"/news/press-releases/2021/curasight-as-presents-at-nordnet-live---spotlight-small-cap-investor-conference-15-april-2021/"},{"d":"2021-05-04","n":"Curasight announces appointment of Dr. Kirsten Drejer as new board member","u":"/news/press-releases/2021/curasight-announces-appointment-of-dr-kirsten-drejer-as-new-board-member/"},{"d":"2021-05-17","n":"Curasight is awarded two prizes in Best IPO 2020 by the independent IPO Guide","u":"/news/press-releases/2021/curasight-is-awarded-two-prizes-in-best-ipo-2020-by-the-independent-ipo-guide/"},{"d":"2021-05-18","n":"Notice of Extraordinary General Meeting","u":"/news/press-releases/2021/notice-of-extraordinary-general-meeting/"},{"d":"2021-05-20","n":"Interim report January – March 2021","u":"/news/press-releases/2021/interim-report-january--march-2021/"},{"d":"2021-05-20","n":"Interim report January – March 2021 – Correction","u":"/news/press-releases/2021/interim-report-january--march-2021--correction/"},{"d":"2021-05-21","n":"Curasight presents at Erik Penser Bank – Temadag Medicinsk Bildteknik & Diagnostik","u":"/news/press-releases/2021/curasight-presents-at-erik-penser-bank--temadag-medicinsk-bildteknik--diagnostik/"},{"d":"2021-05-26","n":"Curasight presents at Bio Stock Life Science Spring Summit","u":"/news/press-releases/2021/curasight-presents-at-bio-stock-life-science-spring-summit/"},{"d":"2021-06-01","n":"Minutes from the Extraordinary General Meeting in Curasight A/S","u":"/news/press-releases/2021/minutes-from-the-extraordinary-general-meeting-in-curasight-as/"},{"d":"2021-06-18","n":"SEB initiates commissioned research on Curasight A/S","u":"/news/press-releases/2021/seb-initiates-commissioned-research-on-curasight-as/"},{"d":"2021-06-24","n":"Positive data of uTREAT® in glioblastoma provides “green light” to proceed with next steps","u":"/news/press-releases/2021/positive-data-of-utreat-in-glioblastoma-provides-green-light-to-proceed-with-next-steps/"},{"d":"2020-09-03","n":"The subscription period in Curasight’s issue of units starts today","u":"/news/press-releases/2020/the-subscription-period-in-curasights-issue-of-units-starts-today/"},{"d":"2020-09-02","n":"Curasight A/S receives approval for listing and publishes prospectus","u":"/news/press-releases/2020/curasight-as-receives-approval-for-listing-and-publishes-prospectus/"},{"d":"2020-09-09","n":"Webcast with Curasight","u":"/news/press-releases/2020/webcast-with-curasight/"},{"d":"2020-09-22","n":"Significantly oversubscribed IPO of units in Curasight","u":"/news/press-releases/2020/significantly-oversubscribed-ipo-of-units-in-curasight/"},{"d":"2020-10-08","n":"First day of trading in Curasight’s shares and warrants at Spotlight Stock Market","u":"/news/press-releases/202
2710/first-day-of-trading-in-curasights-shares-and-warrants-at-spotlight-stock-market/"},{"d":"2020-10-07","n":"Prolongation and expansion of agreement with TRT Innovations ApS","u":"/news/press-releases/2020/prolongation-and-expansion-of-agreement-with-trt-innovations-aps/"},{"d":"2020-10-22","n":"Canadian patent application relating to uTRACE[®] is ready for allowance in Canada","u":"/news/press-releases/2020/canadian-patent-application-relating-to-utrace-is-ready-for-allowance-in-canada/"},{"d":"2020-11-11","n":"Curasight initiates pre-clinical study on therapy (uTREAT[®]) in brain cancer and signs CRO-agreement","u":"/news/press-releases/2020/curasight-initiates-pre-clinical-study-on-therapy-utreat-in-brain-cancer-and-signs-cro-agreement/"},{"d":"2020-11-30","n":"Interim report January – September 2020","u":"/news/press-releases/2020/interim-report-january--september-2020/"},{"d":"2020-12-15","n":"Financial Calendar 2021","u":"/news/press-releases/2020/financial-calendar-2021/"},{"d":"2020-12-16","n":"Japanese patent application 2019-005811 is accepted for grant","u":"/news/press-releases/2020/japanese-patent-application-2019-005811-is-accepted-for-grant/"},{"d":"2020-12-21","n":"Results from Phase II study in prostate cancer to be published in the Journal of Nuclear Medicine","u":"/news/press-releases/2020/results-from-phase-ii-study-in-prostate-cancer-to-be-published-in-the-journal-of-nuclear-medicine/"},{"d":"2024-02-13","n":"Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy","u":"/investor/archive-financing/rights-issue-2024/curasight-resolves-on-a-rights-issue-of-up-to-dkk-51-2-million-to-accelerate-its-therapeutic-strategy/"},{"d":"2024-02-22","n":"Curasight publishes information memorandum in connection with forthcoming rights issue","u":"/investor/archive-financing/rights-issue-2024/curasight-publishes-information-memorandum-in-connection-with-forthcoming-rights-issue/"},{"d":"2024-02-23","n":"The subscription period in Curasight’s rights issue begins today","u":"/investor/archive-financing/rights-issue-2024/the-subscription-period-in-curasights-rights-issue-begins-today/"}]</div>
272    
273        <a class="_download" href="https://publish.ne.cision.com/papi/ShareHistory/47A3AC7342004193B59A2A499F480A54/csv">Download as Excel</a>
274    
275</figure>
276
277        </div>
278        
279    
280            </div>
281        
282				</div>
283			</div>
284			
285		</div>
286	
287		<div data-id="74-4" class="_section-container">
288			
289			<div class="_section">
290				<div class="_grid">
291					
292            <div id="_74-5" class="_block">
293                
294        
295        <div class="_block-content">
296            
297<table class="share-performance">
298    <caption>
299        <h2>Performance</h2>
300    </caption>
301    <tbody>
302        <tr>
303            <th scope="row">Symbol</th>
304            <td>CURAS</td>
305        </tr>
306        <tr>
307            <th scope="row">Currency</th>
308            <td>DKK </td>
309        </tr>
310        <tr>
311            <th scope="row">Market Place</th>
312            <td>XSAT </td>
313        </tr>
314        <tr>
315            <th scope="row">Latest Price</th>
316            <td><span class="_ticker-price"></span></td>
317        </tr>
318        <tr>
319            <th scope="row">Latest Change</th>
320            <td><span data-tickerformat="D MMM, YYYY" data-when="QuoteTime"></span></td>
321        </tr>
322        <tr>
323            <th scope="row">AT High</th>
324            <td><span data-tickerformat="D MMM, YYYY" data-when="AthDate"></span></td>
325        </tr>
326        <tr>
327            <th scope="row">AT Low</th>
328            <td><span data-tickerformat="D MMM, YYYY" data-when="AtlDate"></span></td>
329        </tr>
330        <tr>
331            <th>Year High</th>
332            <td><span class="_ticker-high1y"></span></td>
333        </tr>
334        <tr>
335            <th>Year Low</th>
336            <td><span class="_ticker-low1y"></span></td>
337        </tr>
338        <tr>
339            <th>NumberofShares</th>
340            <td><span class="_ticker-noofshares"></span></td>
341        </tr>
342    </tbody>
343</table>
344        </div>
345        
346    
347            </div>
348        
349				</div>
350			</div>
351			
352		</div>
353	
354		<div data-id="74-3" class="_section-container">
355			
356			<div class="_section">
357				<div class="_grid">
358					
359            <div id="_74-4" class="_block">
360                
361        
362        <div class="_block-content">
363            <h2>Trades</h2><table class="_trades" data-key="7D74DD26506D46E98B94764025870F3C">
364    <thead>
365        <tr>
366            <th>Price</th>
367            <th>Volume</th>
368            <th>
368Buyer</th>
369            <th>Seller</th>
370            <th>Time</th>
371        </tr>
372    </thead>
373    <tbody></tbody>
374</table>
375
376        </div>
377        
378    
379            </div>
380        
381				</div>
382			</div>
383			
384		</div>
385	
386		<div data-id="74-5" class="_section-container">
387			
388			<div class="_section">
389				<div class="_grid">
390					
391            <div id="_74-6" class="_block">
392                
393        
394        <div class="_block-content">
395            <h2>Order book</h2><table class="_orderbook" data-key="1B246F975B8E425FAFD7E55C50C132CC" data-buycolor="#707070" data-sellcolor="#446084 ">
396    <thead>
397        <tr>
398            <th>Buy</th>
399            <th>Volume</th>
400            <th>&nbsp;</th>
401            <th>&nbsp;</th>
402            <th>Volume</th>
403            <th>Sell</th>
404        </tr>
405    </thead>
406    <tbody></tbody>
407</table>
408
409        </div>
410        
411    
412            </div>
413        
414				</div>
415			</div>
416			
417		</div>
418	</main></div><footer>
419		<div data-id="11-1" class="_section-container background-mediumgrey space">
420			
421			<div class="_section">
422				<div class="_grid">
423					
424            <div id="_11-5" class="_block">
425                
426        
427        <div class="_block-content">
428            
429<img src="/files/images/curasight-site-logo.png" alt="Curasight" class="footer-logo" />
430
431        </div>
432        
433    
434            </div>
435        
436            <div id="_11-4" class="_block">
437                
438        
439        <div class="_block-content">
440            <h2>Subscribe</h2><p>Subscribe to get the latest news first.</p>
441
442<form action="//publish.ne.cision.com/Subscription/Subscribe" method="post" class="_subscribe">
443    <input type="hidden" name="subscriptionUniqueIdentifier" value="3094420cd5"/>
444    <input type="hidden" name="Replylanguage" value="en"/> 
445    <div class="_fields">
446        <div id="9874188198243439"></div>
447        <input style="display: none;" name="Language" type="checkbox" checked value="en">
448        <h3>Choose type</h3>
449        <div class="types">
450            
451            <label><input name="informationtype" type="checkbox" value="kmk,rpt,rdv"><span>Financial reports</span></label>
452            
453            <label><input name="informationtype" type="checkbox" value="prm"><span>Press releases</span></label>
454            
455        </div>
456        <label>
457            <span>E-mail</span>
458            <input required type="email" name="Email" placeholder="E-mail">
459            <div class="_result _fail">Something went wrong - please make sure you entered the correct email.</div>
460        </label>
461        
462        <div class="_privacynotice"><p><em data-renderer-mark="true">I consent to Curasight handling my personal data. See Curasight's&nbsp;<a data-testid="link-with-safety" href="/terms-of-use/" title="/terms-of-use/" data-renderer-mark="true" class="css-1rn59kg">Terms of Use</a> for information about how we handle personal data.</em></p></div><button><span>Subscribe</span></button>
463    </div>
464    <div class="_result _success">Thank you. You will get an e-mail message to activate your subscription.</div>
465</form>
466
467
468        </div>
469        
470    
471            </div>
472        
473            <div id="_11-1" class="_block">
474                
475        
476        <div class="_block-content">
477            <p>Curasight is a clinical-stage radiopharmaceutical company advancing uTREAT<sup>®</sup>, a first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat aggressive solid tumors across multiple indications. uTREAT<sup>®</sup> is supported by the clinically validated imaging agent uTRACE<sup>®</sup>, built on the same uPAR-targeting ligand, enabling a differentiated and de-risked theranostic approach.</p>
478<p>uPAR (urokinase-type plasminogen activator receptor) is broadly expressed in aggressive cancers and plays a central role in tumor invasion, angiogenesis, and metastasis. By focusing on this validated and widely expressed target, Curasight is pursuing a therapeutic strategy across multiple high-unmet-need solid tumors using a shared biological target and targeting ligand.</p>
479<p><strong>One target. One therapy. A pipeline-in-a-drug across aggressive solid tumors.</strong></p>
480        </div>
481        
482    
483            </div>
484        
485				</div>
486			</div>
487			
488		</div>
489	
490		<div data-id="11-2" class="_section-container background-darkgrey">
491			
492			<div class="_section">
493				<div class="_grid">
494					
495            <div id="_11-3" class="_block">
496                
497        
498        <div class="_block-content">
499            
500
501<div class="footer--bottom">
502
503    <a href="#top" class="back-to-top">
504        <svg role="img" aria-label="Back to top" width="16" viewB
504ox="0 0 26 26"><use xlink:href="#svg-Nav-hide"></use></svg>
505    </a>
506    
507    <ul class="footer__nav"><li><a href="/news/">News and Media</a></li><li><a href="/contact/">Contact</a></li><li><a href="/terms-of-use/">Terms of use</a></li></ul>
508    
509    
510    <p class="footer__copyright">Copyright 2026 &copy; <strong>Curasight</strong></p>
511    
512</div>
513    
514
515
516    
517
518    
519    
520
521
522        </div>
523        
524    
525            </div>
526        
527				</div>
528			</div>
529			
530		</div>
531	</footer>
532    
533<div id="_cookiebanner-opt-in-out" class="hidden _cookiebanner-opt-in-out" data-nosnippet="true">
534    <div class="_cookiebanner-opt-in-out--inner">
535        <p>This website uses cookies to provide the best possible user experience. If you continue without making any changes you allow this.
536<a href="/terms-of-use/">Read more about cookies here</a></p>
537        <div class="_cookie-buttons">
538            <button><span>Accept</span></button> 
539        </div>
540
541        
542
543    </div>
544    
545</div>
546
547    
548
549
550<script nonce="/Nix+QO9Op5fAhq+qJNB0Q==">window.waasconfig = {"lang":"en","pageId":74,"template":1,"gaoptout":true,"consentFunctions":[],"initFunctions":[],"cleanupFunctions":[],"optout":true,"plausible":"curasight.com","thousandDelimiter":"","decimalSign":"","youtubedisclaimer":"","youtubeaccept":"","vimeodisclaimer":"","vimeoaccept":"","mapsdisclaimer":"","mapsaccept":""};</script>
550<script src="/main.js?1774614054815"></script>
550
551
552
553    
553<script defer src="/api/analytics/"></script>
553
554
555		<div class="overlay-cover"></div>
556    <div class="overlay" aria-hidden="true">
557        <div class="overlay__outer">
558            <div class="overlay__inner">
559                <button class="overlay__close">Close</button>
560                <div class="overlay__content"></div>
561            </div>
562        </div>
563    </div>
564</body>
565</html>

Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.